Kate Therapeutics
Natalie Johnston, currently a Senior Research Associate at Kate Therapeutics, has a rich background in bioengineering and research. Prior to their current role, Natalie held positions at Rejuvenate Bio, BPS Bioscience Inc., and San Diego County Public Health, showcasing their expertise in microbiology and laboratory work. Natalie has also been involved in educational initiatives at Teach For America and research projects at iGEM Foundation. With a Bachelor of Science in Bioengineering from the University of Washington, their research interests include genetic circuits and cell line development.
Kate Therapeutics
Kate Therapeutics (KateTx) is a patient-focused biotechnology company developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined muscle and heart diseases. The company is applying novel technology platforms that directly address the key limitations of current gene therapies, including tissue-specific delivery and gene regulation. These breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies.